General MedicationsINJECTIONStandard
BKEMV
ECULIZUMAB-AEEB
Standard Dose
300MG/30ML(10MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary
Approval overview BKEMV is listed in Drugs@FDA under application 761333 (BLA).
Review priority: N/A Marketing status: Prescription Active ingredient ECULIZUMAB-AEEB Form and strength INJECTABLE;INJECTION - 300MG/30ML(10MG/ML) Sponsor AMGEN INC Submission history Latest submission status date: 2026-03-26 00:00:00.
Structured Monograph
Clinical summary
Approval overview BKEMV is listed in Drugs@FDA under application 761333 (BLA). Review priority: N/A Marketing status: Prescription Active ingredient ECULIZUMAB-AEEB Form and strength INJECTABLE;INJECTION - 300MG/30ML(10MG/ML) Sponsor AMGEN INC Submission history Latest submission status date: 2026-03-26 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: N/A
Interaction Notes
- No interaction notes stored yet.